Parekh, Rajen http://orcid.org/0000-0002-6955-1447
Zhang, Xian
Ungaro, Ryan C.
Brenner, Erica J.
Agrawal, Manasi
Colombel, Jean-Frederic
Kappelman, Michael D.
Funding for this research was provided by:
Leona M. and Harry B. Helmsley Charitable Trust
National Center for Advancing Translational Sciences
Pfizer
Takeda Pharmaceuticals U.S.A.
Janssen Pharmaceuticals
AbbVie
Eli Lilly and Company
Genentech
Boehringer Ingelheim
Bristol-Myers Squibb
Celltrion Healthcare
Arenapharm
Article History
Received: 23 March 2021
Accepted: 13 May 2021
First Online: 28 June 2021
Declarations
:
: RP reports no conflict of interest. XZ reports no conflict of interest. RCU has served as a consultant and/or advisory board member for Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer and Takeda. He has received research support from AbbVie, Boehringer Ingelheim and Pfizer. He is supported by a Career Development Award from the National Institutes of Health (K23KD111995‐01A1). EJB reports no conflict of interest. MA reports no conflict of interest. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development and Genfit. MDK has consulted for Abbvie, Janssen, Pfizer, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm.
: Each SECURE-IBD survey item met criteria for de-identified data, in accordance with the HIPAA Safe Harbor De-Identification standards. The UNC-Chapel Hill Office for Human Research Ethics has determined that the storage and analysis of de-identified data for this project does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.